From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs

Drug Testing and Analysis

Volumn 6, Issue 7-8, 2014, Pages 614-632

  Morris, Hamilton ^a   Wallach, Jason ^b  

^a NEW SCHOOL FOR SOCIAL RESEARCH   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Arylcyclohexylamines; Dissociatives; Folk pharmacology; Internet drug forums; Ketamine; Methoxetamine; NMDA; PCP; Phencyclidine; Research chemicals

Indexed keywords

AMINES; DISSOCIATION; DRUG PRODUCTS;

ARYLCYCLOHEXYLAMINE; DISSOCIATIVE; FOLK PHARMACOLOGY; INTERNET DRUG FORUM; KETAMINE; METHOXETAMINE; NMDA; PCP; PHENCYCLIDINE; RESEARCH CHEMICAL;

COMMERCE;

AMANTADINE; DEXTROMETHORPHAN; ETICYCLIDINE; ILLICIT DRUG; KETAMINE; METHOXETAMINE; PHENCYCLIDINE; PIPERIDINE; UNCLASSIFIED DRUG; 2-(3-METHOXYPHENYL)-2-(ETHYLAMINO)CYCLOHEXANONE; ANESTHETIC AGENT; CYCLOHEXANONE DERIVATIVE; CYCLOHEXYLAMINE DERIVATIVE; STREET DRUG;

DRUG ABUSE; DRUG MISUSE; INTERNET; PRIORITY JOURNAL; REVIEW; SYNTHESIS; CHEMISTRY; HUMAN;

ANESTHETICS, DISSOCIATIVE; CYCLOHEXANONES; CYCLOHEXYLAMINES; HUMANS; INTERNET; PHENCYCLIDINE; STREET DRUGS;

EID: 84904582684     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1620     Document Type: Review

References (210)

1. E.F. Domino . Taming the ketamine tiger. Anesthesiology 2010, 113, 678.
2. N. Anis, S. Berry, N. Burton, D. Lodge . The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by n-mfethyl-aspartate. Brit. J. Pharmacol. 1983, 79, 565.
3. A. Mori, Y. Noda, T. Mamiya, Y. Miyamoto, A. Nakajima, H. Furukawa, T. Nabeshima . Phencyclidine-induced discriminative stimulus is mediated via phencyclidine binding sites on the n-methyl-d-aspartate receptor-ion channel complex, not via sigma1 receptors. Behav. Brain Res. 2001, 119, 33.
4. P.L. Herrling . Excitatory Amino Acids: Clinical Results with Antagonists. Academic Press, California, 1997.
5. G.W. Albers, W.M. Clark, R.P. Atkinson, K. Madden, J.L. Data, M.J. Whitehouse . Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. Stroke 1999, 30, 508.
6. R.B. Rothman, A.A. Reid, J.A. Monn, A.E. Jacobson, K.C. Rice . The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: Evidence for n-methyl-d-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites. Mol. Pharmacol. 1989, 36, 887.
7. B.L. Roth, S. Gibbons, W. Arunotayanun, X.-P. Huang, V. Setola, R. Treble, L. Iversen . The ketamine analogue methoxetamine and 3-and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PloS One 2013, 8, e59334.
8. K.L.R. Jansen . Ketamine: Dreams and Realities. MAPS, California, 2004.
9. D. Lodge, W. Danysz, C.G. Parsons . Ionotropic glutamate receptors as therapeutic targets. F.P Graham Publishing Co., 2002.
10. F.X. Vollenweider, K.L. Leenders, C. Scharfetter, P. Maguire, O. Stadelmann, J. Angst . Positron emission Johnson City, TN tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997, 16, 357.
11. C.J. Reissig, L.P. Carter, M.W. Johnson, M.Z. Mintzer, M.A. Klinedinst, R.R. Griffiths . High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology 2012, 223, 1.
12. E.F. Domino . History and pharmacology of PCP and PCP-related analogs. J. Psychoactive Drugs 1980, 12, 223.
13. B.A. Killinger, M.M. Peet, L.E. Baker . Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats. Pharmacol. Biochem. Behav. 2010, 96, 260.
14. S. Herling, J.H. Woods . IV. Discriminative stimulus effects of narcotics: Evidence for multiple receptor-mediated actions. Life Sci. 1981, 28, 1571.
15. K.M. Kumor, C.A. Haertzen, R.E. Johnson, T. Kocher, D. Jasinski . Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J. Pharm. Exp. Ther. 1986, 238, 960.
16. C.D. Chambers, J.A. Inciardi, R.C. Stephens . A critical review of pentazocine abuse. HSMHA Health Rep. 1971, 86, 627.
17. K.L. Krystal JH, Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr, Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiat. 1994, 51, 199.
18. E.D. Luby, B.D. Cohen, G. Rosenbaum, J.S. Gottlieb, R. Kelley . Study of a new schizophrenomimetic drug-sernyl. AMA. Arch. Neurol. Psychiatry 1959, 81, 363.
19. J.W. Newcomer, N.B. Farber, V. Jevtovic-Todorovic, G. Selke, A.K. Melson, T. Hershey, S. Craft, J.W. Olney . Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20, 106.
20. J.S. Meyer, F. Greifenstein, M. DeVault . A new drug causing symptoms of sensory deprivation: Neurological, electroencephalographic and pharmalogical effects of sernyl. J. Nerv. Ment. Dis. 1959, 129, 54.
21. D. Carpenter . A psychonaut's guide to the invisible landscape: The topography of the psychedelic experience. Inner Traditions, Vermont, 2006.
22. R.L. Linder, S.E. Lerner, R.S. Burns . PCP, the Devil's Dust: Recognition, Management, and Prevention of Phencyclidine Abuse. Wadsworth Publishing Company, California, 1981.
23. E. Studerus, A. Gamma, F.X. Vollenweider . Psychometric evaluation of the altered states of consciousness rating scale (OAV). PloS One 2010, 5, e12412.
24. N. Kursanov . Phenyl derivatives of naphthenes, second paper, some derivatives of phenylcyclohexane. Zh. Russ. Fiz.-Khim. O-va. 1907, 38, 1295.
25. S. Chiavarelli, E.F. Rogers, G.B. Marino-Bettolo . Researches on synthetic products with erythrina akaloids as a model. Gazz. Chim. Ital. 1953, 83, 347.
26. K. Thomae . Verafahren zur herstellung von tertiären aminen, ihren säureadditionssalzen und quaternären ammoniumverbindugen. Patent No. 1124496, 1962.
27. V.H. Maddox . The historical development of phencyclidine, in PCP (Phencyclidine): Historical and Current Perspectives. (Ed: E. Domino ). NPP Books: Michigan, 1981, pp. 1-8.
28. G. Chen, C.R. Ensor, D. Russell, B. Bohner . The pharmacology of 1-(1-phenylcyclohexyl) piperidine-HCl. J. Pharm. Exp. Ther. 1959, 127, 241.
29. F.E. Greifenstein, J. Yoshitake, M. DeVault, J.E. Gajewski . A study of 1-aryl cyclohexylamine for anesthesia. Anesth. Analg. 1958, 5, 283.
30. G. Chen . The neuropharmacology of phencyclidine, in PCP (phencyclidine), historical and current perspectives, (Ed: E.F. Domino ). NPP Books, Michigan, 1981, pp. 9.
31. E. Lear . Intravenous anesthesia: A survery of newer agents. Anesth. Analg. 1968, 47, 154.
32. E.F. Domino . Chemical dissociation of human awareness: Focus on non-competitive NMDA receptor antagonists. J. Psychopharmacol. 1992, 6, 418.
33. E.F. Domino, P. Chodoff, G. Corssen . Pharmacological effects of CI-581, a new dissociative anaesthetic, in man. Clin. Pharmacol. Ther. 1965, 6, 279.
34. C.L. Stevens . Aminoketones and methods for their production. US Patent No. 3254124, 1966.
35. ACMD. Ketamine Report. Available at: https://www.gov.uk/government/publications/ketamine-report [7 January 2014].
36. H.W. Feldman . PCP use in four cities: An overview, in Angel Dust, an Ethnographic Study of PCP Users. (Eds: H.W. Feldman, M. Agar, G.M. Beschner ). Lexington Books: Massachusetts, 1979, pp. 29.
37. P.C.P. "T.H.C." and the Ripoff Syndrome. Do It Now Foundation, Institute For Chemical Survival, Arizona, 1975.
38. Anon. The 1977 street drug analysis results. Clin. Toxicol. 1979, 14, 619.
39. G.D. Lundberg, R.C. Gupta, S.H. Montgomery . Phencyclidine: Patterns seen in street drug analysis. Clin. Toxicol. 1976, 9, 503.
40. Drug Enforcement Agency. Information bulletin. PCP tablets sold as MDMA. Available at: www.justice.gov/archive/ndic/pubs0/661/index.htm [7 January 2014].
41. P. Jenkins . Synthetic Panics: The Symbolic Politics of Designer Drugs. New York University Press, NY, USA, 1999.
42. J.P. Morgan, D. Kagan . The dusting of America: The image of phencyclidine (PCP) in the popular media. J. Psychoactive Drugs. 1980, 12, 195.
43. Drug Enforcement Adminsitration. Office of Diversion Control. Phencyclidine. Available at: http://www.deadiversion.usdoj.gov/drug_chem_info/pcp.pdf [7 January 2014].
44. UNDOC. World Drug Report 2010. United Nations Office on Drugs and Crime, United Nations Publications, New York, 2010.
45. R.L. McQuinn, E.J. Cone, H.E. Shannon, T.-P. Su . Structure-activity relationships of the cycloalkyl ring of phencyclidine. J. Med. Chem. 1981, 24, 1429.
46. A. Thurkauf, B. De Costa, S. Yamaguchi, M.V. Mattson, A.E. Jacobson, K.C. Rice, M.A. Rogawski . Synthesis and anticonvulsant activity of 1-phenylcyclohexylamine analogs. J. Med. Chem. 1990, 33, 1452.
47. A.C. Allen, J. Robles, W. Dovenski, S. Calderon . PCP: A review of synthetic methods for forensic clandestine investigation. Forensic Sci. Int. 1993, 61, 85.
48. R.E. Garey . PCP (phencyclidine): An update. J. Psychoactive Drugs 1979, 11, 265.
49. R.C. Petersen, R.C. Stillman . Phencyclidine: An overview, in Phencyclidine Abuse: An Appraisal. (Eds: R.C. Peterson, R.C. Stillman ). NIDA Res. Monogr.: Rockville, Maryland, 1978, 21, pp. 1-17.
50. A.T. Shulgin, D.E. MacLean . Illicit synthesis of phencyclidine (PCP) and several of its analogs. Clin. Toxicol. 1976, 9, 553.
51. C. Sauer, F.T. Peters, R.F. Staack, G. Fritschi, H.H. Maurer . New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 2008, 43, 305.
52. P. Roesner, T. Junge, G. Fritschi, B. Klein, K. Thielert, M. Kozlowski . Neue synthetische drogen: Piperazin-, Procyclidin-und alpha-Aminopropiophenonderivate. Toxichem. Krimtech. 1999, 66, 81.
53. W.H. Soine, R.L. Balster, K.E. Berglund, C.D. Martin, D.T. Agee . Identification of a new phencyclidine analog, 1-(1-phenylcyclohexyl)-4-methylpiperidine, as a drug of abuse. J. Anal.Toxicol. 1982, 6, 41.
54. J.R. Ballinger, J.A. Marshman . GLC quantitation of 1-piperidinocyclohexanecarbonitrile (PCC) in illicit phencyclidine (PCP). J. Anal.Toxicol. 1979, 3, 158.
55. D.B. Vaupel, D. McCoun, E.J. Cone . Phencyclidine analogs and precursors: Rotarod and lethal dose studies in the mouse. J. Pharm. Exp. Ther. 1984, 230, 20.
56. E.J. Cone, D.B. Vaupel, W.F. Buchwald . Phencyclidine: Detection and measurement of toxic precursors and analogs in illicit samples. J. Anal.Toxicol. 1980, 4, 119.
57. A. Reed, A.W. Kane . Phencyclidine (PCP). STASH Capsules. 1970, 44, 1.
58. Second session, on S. 2778, June 7 and 21, 1978. Phencyclidine (PCP or angel dust). Joint hearings before the Subcommittee on Alcoholism and Drug Abuse of the Committee on Human Resources and the Subcommittee to Investigate Juvenile Delinquency of the Committee on the Judiciary, United States Senate, Ninety-fifth Congress, US Government Printing Office, Washington DC, 1978.
59. Parke, Davis & Co. Heterocyclic compounds for use as central nervous system depressants. UK Patent No. 838748, 1960.
60. J.Q. Beagle . Synthesis and effects of PCP analogs. Rhodium. Available at: http://www.erowid.org/archive/rhodium/chemistry/pcp/ [7 January 2014].
61. The Hive. Xicori. TCP synthesis. Available at: http://chemistry.mdma.ch/hiveboard/methods/000484668.html [7 January 2014].
62. S.E.B. Lerner, R. Stanley . Phencyclidine use among youth: History, epidemiology, and acute and chronic intoxication. California School of Professional Psychology at Berkeley, Berkley, CA, USA, 1978.
63. Drug Enforcement Administration. Lists of: Scheduling actions, controlled substances, regulated chemicals. US Department of Justice, Washington DC, USA, 2013.
64. S.E. Lerner, R.S. Burns . Phencyclidine use among youth: History, epidemiology, and acute and chronic intoxication. NIDA Res. Monogr. 1978, 21, 66.
65. T.A. Dal-Cason, E. Franzosa . Occurrences and forms of the hallucinogens, in Hallucinogens: A Forensic Drug Handbook. (Ed: R.R. Laing ). Academic Press: London, UK, 2003, pp. 37-64.
66. A. Kalir, H. Edery, Z. Pelah, D. Balderman, G. Porath . 1-Phenylcycloalkylamine derivatives. II. synthesis and pharmacological activity. J. Med. Chem. 1969, 12, 473.
67. K. Bailey . Identification of a street drug as N-ethyl-1-phenylcyclohexylamine, a phencyclidine analog. J. Pharm. Sci. 1978, 67, 885.
68. P. Magnusson . PCP-like drug hits street here. The Detroit Free Press. 1977, 18A.
69. J.E. Smialek, J.R. Monforte, R. Gault, W.U. Spitz . Cyclohexamine ("rocket fuel")-phencyclidine's potent analog. J. Anal. Toxicol. 1979, 3, 209.
70. Abuse of dangerous licit and illicit drugs-psychotropics, phencyclidine (PCP), and talwin. Hearings before the Select Committee on Narcotics Abuse and Control, House of Representatives, Ninety-fifth Congress, second session. US Government Printing Office, Washington DC, USA 1979.
71. Anon. 3-Year term given. Kokomo (Ind.) Tribune, 20 October 1981.
72. Anon. 26 people face drug charges. The Globe and Mail, 16 September 1978, 3.
73. Anon. L.A. Daniels . Professor on L.I. accused of plot to make drugs. The New York Times, 28 May 1980, B1.
74. Anon. Charged for drugs. Ironwood Daily Globe, 18 August 1981, 2.
75. U.S. v. Wisniewski. United States Court of Appeals. Seventh Circuit. 741 F.2d 138. No. 84-1089, 1984.
76. Anon. Lewisberry man, 20, to face drug charge. The Patriot-News, 19 July 1991,
77. K.T. Brady, R.L. Balster . Discriminative stimulus properties of phencyclidine and five analogues in the squirrel monkey. Pharmacol. Biochem. Be. 1981, 14, 213.
78. R. Lindsey . Los Angeles police scored on shooting. The New York Times, 15 August 1977, 13.
79. G.R. Nakamura, E.C. Griesemer, L.E. Joiner, T.T. Noguchi . Determination of 1-(1-Phenylcyclohexyl) pyrrolidine (PHP) in postmortem specimens: A case report. Clin. Toxicol. 1979, 14, 383.
80. U.S. v Worthington, 642 F.2d 150. No. 80-5306. United States Court of Appeals, Fifth Circuit, 1981.
81. R.D. Budd . PHP, a new drug of abuse. New Engl. J. Med. 1980, 303, 588.
82. A.J. Giannini, S. Castellani . A case of phenylcyclohexylpyrrolidine (PHP) intoxication treated with physostigmine. Clin. Toxicol. 1982, 19, 505.
83. A.J. Giannini, W.A. Price, R.H. Loiselle, D.W. Malone . Treatment of phenylcyclohexylpyrrolidine (PHP) psychosis with haloperidol. Clin. Toxicol. 1985, 23, 185.
84. U.S. v. Talladino, 38 F.3d 1255. No. 94-1122. United States Court of Appeals. First Circuit, 1994.
85. Bluelight. Adder. PCP analogs (cumulative). Available at: http://www.bluelight.ru/vb/threads/504286-PCP-analogs-(Cumulative) [7 January 2014].
86. B.A. Lodge, R. Duhaime, J. Zamecnik, P. MacMurray, R. Brousseau . New street analogs of phencyclidine. Forensic Sci. Int. 1992, 55, 13.
87. E.J. Cone, R.L. McQuinn, H.E. Shannon . Structure-activity relationship studies of phencyclidine derivatives in rats. J. Pharm. Exp. Ther. 1984, 228, 147.
88. The Hive. Xicori. Bioassay. Available at: http://chemistry.mdma.ch/hiveboard/methods/000386595.html [7 January 2014].
89. The Hive. Xicori. PCM synthesis. Available at: http://chemistry.mdma.ch/hiveboard/methods/000475049.html [7 January 2014].
90. Parke, Davis & Co. Pharmaceutical compositions and methods for producing phenylcyclohexane compounds. US Patent No. 861350, 1961.
91. The Hive. Aurelius, Ethoxyethyl analogue. Available at: http://chemistry.mdma.ch/hiveboard/methods/000451447.html [7 January 2014].
92. The Hive. 4-methoxy PCP-Beagle. Available at: http://chemistry.mdma.ch/hiveboard/novel/000212050.html [7 January 2014].
93. The Hive. Zealot: Synthesis and bioevaluation of PCDE. Available at: http://chemistry.mdma.ch/hiveboard/novel/000369598.html#Post369598 [7 January 2014].
94. The Hive. Beagle. Novel PCP analog. Available at: http://chemistry.mdma.ch/hiveboard/novel/000108806.html [7 January 2014].
95. National drug threat assessment: Ketamine. National Drug Intelligence Center. Available at: http://www.justice.gov/archive/ndic/pubs8/8731/odd.htm#Ketamine [7 January 2014].
96. National Drug Intelligence Center. Intelligence Bulletin: Ketamine. Available at: http://www.justice.gov/archive/ndic/pubs10/10255/10255t.htm [7 January 2014].
97. R.K. Siegel . Phencyclidine and ketamine intoxication: A study of four populations of recreational users. NIDA Res. Monogr. 1978, 21, 119.
98. C.E. Reier . Ketamine-" dissociative agent" or hallucinogen? New Engl. J. Med. 1971, 284, 791.
99. M. Moore, H.S. Alltounian . Journeys into the Bright World. Para Research, Massachusetts, 1978.
100. J.C. Lilly . The Scientist: A Metaphysical Autobiography. Ronin Publishing, California, 1978.
101. Ketamine abuse. FDA Drug Bulletin. U.S. Department of Health and Human Services. Food and Drug Administration: Silver Spring, MD, 1979.
102. U.S. Department of Justice. Lists of: Scheduling Actions Controlled Substances Regulated Chemicals. Drug Enforcement Administration. Available at: http://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf [7 January 2014].
103. L.P. Brown . Pulse Check: National Trends in Drug Abuse. DIANE Publishing, Pennsylvania, 1995.
104. The Dextroverse. The DXM Zine. Issue 2. Available at: http://dextroverse.org/zine/zine2/ [7 January 2014].
105. The Dextroverse. The DXM Zine. Issue 1. Available at: http://dextroverse.org/zine/zine1/ [7 January 2014].
106. P.S. Chu, S. Kwok, K. Lam, T. Chu, S.W. Chan, C. Man, W. Ma, K. Chui, M. Yiu, Y. Chan . Street ketamine'-associated bladder dysfunction: A report of ten cases. Hong Kong Med. J. 2007, 13, 311.
107. K. Shahzad . Understanding mechanisms of ketamine-induced human urinary tract damage, MSc by research thesis. University of York: York, UK, 2011.
108. EMCDDA. Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs. EMCDDA, Lisbon. Available at: http://www.emcdda.europa.eu/html.cfm/index33341EN.html [7 January 2014].
109. R.R. Laing . Hallucinogens: A Forensic Drug Handbook. Academic Press, 2003.
110. T. Thacker . Ketamine to be sold only with prescription. The Indian Express, 1 November 2010.
111. G. Chen, C.R. Ensor, B. Bohner . The pharmacology of 2-(ethylamino)-2-(2-thienyl)-cyclohexanone·HCl (CI-634). J. Pharm. Exp. Ther. 1969, 168, 171.
112. R.F. Parcell . 2-(Ethylamino)-2-(2-thienyl)cyclohexanone and acid addition salts. US Patent No. 3522273, 1970.
113. H. Chung, H. Choi, E. Kim, W. Jin, H. Lee, Y. Yoo . A fatality due to injection of tiletamine and zolazepam. J. Anal.Toxicol. 2000, 24, 305.
114. C.C. Lee, Y.Y. Lin, C.W. Hsu, S.J. Chu, S.H. Tsai . Movement disorder caused by abuse of veterinary anesthesia containing tiletamine. Am. J. Emerg. Med. 2009, 27, 1022 e5-6.
115. Toad. Trick or Treat? Available at: http://www.erowid.org/experiences/exp.php?ID=10352 [7 January 2014].
116. Erowid. Undervet. Careful with this Benzo/Dissociative Combo. Available at: http://www.erowid.org/experiences/exp.php?ID=86014 [7 January 2014].
117. O. Schnider, A. Grüssner . Hydrophenanthrene derivatives and process for the manufacture of same. US Patent No. 2, 524, 855, 1950.
118. Roche Products Ltd. The resolution of 3-hydroxy- and 3-methoxy-N-methyl-morphinanes and process for the manufacture of the latter. Patent No. 684, 367, 1952.
119. J. Church, D. Lodge, S.C. Berry . Differential effects of dextrorphan and levorphanol on the excitation of rat spinal neurons by amino acids. Eur. J. Pharmacol. 1985, 111, 185.
120. Y.-C. Chou, J.-F. Liao, W.-Y. Chang, M.-F. Lin, C.-F. Chen . Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res. 1999, 821, 516.
121. G. Albers, R. Atkinson, R. Kelley, D. Rosenbaum . Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 1995, 26, 254.
122. J. Gelfer . Towards a sacramental understanding of dextromethorphan. JASANAS 2007, 3, 80.
123. R. Chapman . Soft Machine. Mojo 1997.
124. R.H. Schwartz . Adolescent abuse of dextromethorphan. Clin. Pediatr. 2005, 44, 565.
125. A. Dodds, E. Reval . Toxic psychosis due to dextromethorphan. Med. J. Aust. 1967, 2, 231.
126. R. Degkwitz . Dextromethorphan (romilar) as an intoxicating agent. Der Nervenarzt. 1964, 35, 412.
127. R.E. Long, P.P. Penna . Drugs of Abuse. A guide for the professions..drug abuse education. American Pharmaceutical Association: Washington, DC, 1968.
128. D. Jasinski, W. Martin, P. Mansky . Progress report on the assessment of the antagonists nalbuphine and GPA-2087 for abuse potential and studies of the effects of dextromethorphan in man. National Academy of Science/National Research Council, Washington DC, 1971, pp. 143.
129. A.T. Shulgin . Drugs of abuse in the future. Clin. Toxicol. 1975, 8, 405.
130. L. Rammer, P. Holmgren, H. Sandler . Fatal intoxication by dextromethorphan: A report on two cases. Forensic Sci. Int. 1988, 37, 233.
131. W.E. White . The Dextromethorphan FAQ. 1994. Available at: http://www.zoklet.net/totse/en/drugs/rare_and_exotic_drugs/dext.html [7 January 2014].
132. S.P. Nordt . DXM: A new drug of abuse? Ann. Emerg. Med. 1998, 31, 794.
133. M.D. Wilson, R.W. Ferguson, M.E. Mazer, T.L. Litovitz . Monitoring trends in dextromethorphan abuse using the national poison data system: 2000-2010. Clin. Toxicol. 2011, 49, 409.
134. National Drug Intelligence Center. Intelligence Bulletin: DXM (dextromethorphan). Available at: http://www.justice.gov/archive/ndic/pubs11/11563/ [7 January 2014].
135. FDA Drug Safety and Risk Management Advisory Committee. Abuse Potential of Dextromethorphan. Available at: http://www.erowid.org/chemicals/dxm/dxm_article4.pdf [7 January 2014].
136. K.W. Muir, K.R. Lees . Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995, 26, 503.
137. M.E. Christy, P.S. Anderson, S.F. Britcher, C.D. Colton, B.E. Evans, D.C. Remy, E.L. Engelhardt . Transannular reactions of dibenzo [a, d] cycloalkenes. 1. Synthesis of dibenzo [a, d] cycloocten-6, 12-imines and dibenzo [a, d] cyclohepten-5, 10-imines. J. Org. Chem. 1979, 44, 3117.
138. E.H. Wong, J.A. Kemp, T. Priestley, A.R. Knight, G.N. Woodruff, L.L. Iversen . The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. P. Natl. Acad. Sci. 1986, 83, 7104.
139. L. Velíšek, P. Mareš . Developmental aspects of the anticonvulsant action of MK-801 in Multiple sigma and PCP receptor ligands: mechanisms for neuromodulation and neuroprotection. (Ed: J.M.D. Kamenka ). NPP Books: Ann Arbor, Michigan, 1992, pp. 779-795.
140. Cat. alt.religion.psychedelic.moderated. Available at: https://groups.google.com/d/msg/alt.drugs.chemistry/FkteiXaZIqM/p4CL3U-Trd8J [7 November 2013].
141. A. Mozayani, P. Schrode, J. Carter, T.J. Danielson . A multiple drug fatality involving MK-801 (dizocilpine), a mimic of phencyclidine. Forensic Sci. Int. 2003, 133, 113.
142. Bluelight. Tantric. mk-801 trip report, all systems go. Available at: http://www.bluelight.ru/vb/threads/141296-MK-801-first-few-experiences-All-systems-go [7 January 2014].
143. Erowid. Viscosity. The Most Beautiful Lobotomy I Ever Had. Available at: http://www.erowid.org/experiences/exp.php?ID=94476 [7 January 2014].
144. J.W. Olney, J. Labruyere, M.T. Price . Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244, 1360.
145. M. Schmutz, A. Arthur, H. Faleck, G. Karisson, A. Kotake, L. Lantwicki, L. LaRue, S. Markabi, D. Murphy, M. Powell, D. Sauer . Selfotel (CGS19755), in Excitatory Amino Acids: Clinical Results with Antagonists. (Ed: P. Herrling ), Academic Press: London, 1997, pp. 1-6.
146. H. Hirbec, M. Gaviria, J. Vignon . Gacyclidine: A new neuroprotective agent acting at the N-methyl-D-aspartate receptor. CNS Drug Rev. 2001, 7, 172.
147. G.C. Palmer, J.B. Hutchison . Preclinical and clinical aspects of remacemide hydrochloride, in Excitatory Amino Acids: Clinical Results with Antagonists. (Ed: P. Herrling ). Academic Press: London, 1997, pp. 109-124.
148. A.S. Fix, J.W. Horn, K.A. Wightman, C.A. Johnson, G.G. Long, R.W. Storts, N. Farber, D.F. Wozniak, J.W. Olney . Neuronal vacuolization and necrosis induced by the noncompetitive n-methyl-d-aspartate (NMDA) antagonist MK (+) 801 (dizocilpine maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neurol. 1993, 123, 204.
149. N.B. Farber, J. Hanslick, C. Kirby, L. McWilliams, J.W. Olney . Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology 1998, 18, 57.
150. J. Kornhuber, M. Weller, K. Schoppmeyer, P.J. Riederer . Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural Transm. Suppl. 1994, 43, 91.
151. C. Parsons, W. Danysz, G. Quack . Memantine is a clinically well tolerated n-methyl-d-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999, 38, 735.
152. Lazyvegan. Memantine hydrochloride: A few words of caution. Etheogen Rev. 2003, 12, 132.
153. Erowid. CaptainOubliz. Almost Mushroomesque. Available at: http://www.erowid.org/experiences/exp.php?ID=100894 [7 January 2014].
154. Erowid. E.-d. tripper. Nearly Neverending Trip. Available at: http://www.erowid.org/experiences/exp.php?ID=52958 [7 January 2014].
155. R. Monastero, C. Camarda, C. Pipia, R. Camarda . Visual hallucinations and agitation in Alzheimer's disease due to memantine: Report of three cases. JNNP 2007, 78, 546.
156. D.R. Spiegel, M.R. Leader . Psychosis induced by the interaction of memantine and amantadine: Lending evidence to the glutamatergic theory of schizophrenia. Clin. Schizophr. Relat. Psychoses. 2007, 1, 273.
157. K. Zdanys, R.R. Tampi . A systematic review of off-label uses of memantine for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008, 32, 1362.
158. V.H. Maddox, E.F. Godefroi, R.F. Parcell . The synthesis of phencyclidine and other 1-arylcyclohexylamines. J. Med. Chem. 1965, 8, 230.
159. P. Geneste, J.M. Kamenka, S.N. Ung, P. Herrmann, R. Goudal, G. Trouiller . Conformational determination of phencyclidine derivatives in view of structure-activity correlation. Eur. J. Med. Chem. - Chim. Ther. 1979, 14, 301.
160. J. Vignon, J.-P. Vincent, J.-N. Bidard, J.-M. Kamenka, P. Geneste, S. Monier, M. Lazdunski . Biochemical properties of the brain phencyclidine receptor. Eur. J. Pharmacol. 1982, 81, 531.
161. Ecstasydata. 4-MeO-PCP. ID Nos. 2425, 2446, 2339. Available at: http://www.ecstasydata.org/ [7 January 2014].
162. EMCDDA. 2011 Annual report on the state of the drugs problem in Europe. Available at: http://www.emcdda.europa.eu/publications/annual-report/2011 [7 January 2014].
163. J. Casale . 4-Methoxyphencyclidine: An analytical profile. Microgram J. 2011, 8, 39.
164. Bluelight. hugo24. 1-{1-(3-Methoxiphenyl)-cyclohexyl}-piperidin. Available at: http://www.bluelight.ru/vb/archive/index.php/t-427958.html [7 November 2013].
165. J.M. Kamenka, B. Chiche, R. Goudal, P. Geneste, J. Vignon, J.P. Vincent, M. Lazdunski . Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl) piperidine derivatives. J. Med. Chem. 1982, 25, 431.
166. Y. Itzhak . High and low affinity psychotomimetic opioid binding sites: Characterization by a novel 3H-PCP analog. NIDA Res. Monogr. 1986, 75, 173.
167. O. Corazza, S. Assi, F. Schifano . From " special k" to " special m" The evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci. Ther. 2013, 19, 454.
168. M.R. Meyer, M. Bach, J. Welter, M. Bovens, A. Turcant, H.H. Maurer . Ketamine-derived designer drug methoxetamine: Metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn. Anal. Bioanal. Chem. 2013, 405, 6307.
169. E.L. Menzies, S.C. Hudson, P.I. Dargan, M.C. Parkin, D.M. Wood, A.T. Kicman . Characterizing metabolites and potential metabolic pathways for the novel psychoactive substance methoxetamine. Drug Test. Anal. 2013. DOI: 10.1002/dta.1541
170. P.A. Hays, J.F. Casale, A.L. Berrier . The characterization of 2-(3-methoxyphenyl)-2-(ethylamino) cyclohexanone (methoxetamine). Microgram. J. 2012, 9, 3.
171. G. De Paoli, S.D. Brandt, J. Wallach, R.P. Archer, D.J. Pounder . From the street to the laboratory: Analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices. J. Anal. Toxicol. 2013, 37, 277.
172. Anon. Police treated after 'drug' contamination in Harlow. Harlow Star, 21 October 2010.
173. EMCDDA. EMCDDA-Europol 2010 Annual Report on the Implementation of Council Decision 2005/387/JHA. Available at: http://www.emcdda.europa.eu/publications/implementation-reports/2010 [7 January 2014].
174. H. Morris . Interview with a ketamine chemist, or to be more precise, an arylcyclohexylamine chemist. Vice Magazine 2011, 18, 98.
175. J. Ward, S. Rhyee, J. Plansky, E. Boyer . Methoxetamine: A novel ketamine analog and growing health-care concern. Clin. Toxicol. 2011, 49, 874.
176. EMCDDA. Briefing paper: Online sales of new psychoactive substances/ 'legal highs': Summary of results from the 2011 multilingual snapshots. Available at: http://www.emcdda.europa.eu/publications/scientific-studies/2011/snapshot [7 January 2014].
177. Official benzo fury. MXE pellets. Available at: http://www.officialbenzofury.com/products/MXE-Pellets.html# [7 January 2014].
178. D.M. Wood, S. Davies, A. Calapis, J. Ramsey, P.I. Dargan . Novel drugs--novel branding. QJM 2012, 105, 1125.
179. D.M. Wood, S. Davies, M. Puchnarewicz, A. Johnston, P.I. Dargan . Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur. J. Clin. Pharmacol. 2012, 68, 853.
180. J.E. Shields, P.I. Dargan, D.M. Wood, M. Puchnarewicz, S. Davies, W.S. Waring . Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation. Clin. Toxicol. 2012, 50, 438.
181. K.E. Hofer, B. Grager, D.M. Müller, C. Rauber-Lüthy, H. Kupferschmidt, K.M. Rentsch, A. Ceschi . Ketamine-like effects after recreational use of methoxetamine. Ann. Emerg. Med. 2012, 60, 97.
182. D.M. Wood, D.T. Yew, W.P. Lam, P.I Dargan. Chronic methoxetamine exposure in a mouse model demonstrates that methoxetamine is not a 'bladder friendly' alternative to ketamine. Clin. Toxicol. 2012, 50, 574.
183. EMCDDA. 2012 Annual report on the state of the drugs problem in Europe. Available at: http://www.emcdda.europa.eu/publications/annual-report/2012 [7 January 2014].
184. ACMD. Methoxetamine report. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119087/methoxetamine2012.pdf [7 January 2014].
185. EMCDDA. EMCDDA-Europol 2012 Annual Report on the Implementation of Council Decision 2005/387/JHA (New drugs in Europe, 2012). Available at: http://www.emcdda.europa.eu/publications/implementation-reports/2012 [7 January 2014].
186. J. Wallach, G.D. Paoli, A. Adejare, S.D. Brandt . Preparation and analytical characterization of 1-(1-phenylcyclohexyl) piperidine (PCP) and 1-(1-phenylcyclohexyl) pyrrolidine (PCPy) analogues. Drug Test. Anal. 2013, [epub ahead of print]
187. Bluelight. The Small & Handy 3-HO-PCP Thread. Available at: http://www.bluelight.ru/vb/threads/647596-The-Small-amp-Handy-3-HO-PCP-Thread [7 January 2014].
188. Flashback. 3-OH-PCP (3-[1-(1-piperidyl)cyclohexyl]phenol). Available at: https://www.flashback.org/t2100084 [7 November 2013].
189. C.L. Stevens . Aminoétones et leurs procédés de préparation. Patent No. 634208, 1963.
190. Bluelight. Limitbreaker. (N-ethylnorketamine) - above methoxetamine means godlike for me. Available at: http://www.bluelight.ru/vb/threads/636582-%28N-ethylnorketamine%29-Above-methoxetamine-means-godlike-for-me [7 November 2013].
191. E. Christian . Reaction of organo-magnesium compounds on α-amino nitriles. Bull. Soc. Chim. Belg. 1924, 33, 483.
192. M.L. Berger, A. Schweifer, P. Rebernik, F. Hammerschmidt . NMDA receptor affinities of 1, 2-diphenylethylamine and 1-(1, 2-diphenylethyl) piperidine enantiomers and of related compounds. Bioorg. Med. Chem. 2009, 17, 3456.
193. N.M. Gray, B.K. Cheng . Preparation of 1, 2-diarylethylamines for treatment of neurotoxic injury. EU Patent No. EP346791A1, 1989.
194. M.O. Kwon, F. Fischer, M. Matthisson, P. Herrling . List of drugs in development for neurodegenerative diseases. Neurodegener. Dis. 2004, 1, 113.
195. UK Chemical Research. Diphenidine - 1, 2-diphenylethylpiperidine. Available at: http://www.ukchemicalresearch.org/Thread-Diphenidine-1-2-diphenylethylpiperidine?pid=47802#pid47802 [7 January 2014].
196. Bluelight. The big & dandy diphenidine [1-(1, 2-diphenylethyl)piperidine] thread. Available at: http://www.bluelight.ru/vb/threads/668291-The-Big-amp-Dandy-Diphenidine-1-%281-2-diphenylethyl%29piperidine-Thread [7 January 2014].
197. Bluelight. The big & dandy methoxphenidine (2-MeO-Diphenidine) thread. Available at: http://www.bluelight.ru/vb/threads/700834-The-Small-amp-Handy-Methoxphenidine-%282-MeO-Diphenidine%29-Thread [7 January 2014].
198. UK Chemical Research. Methoxphenidine 1-(1-(2-methoxyphenyl)-2-phenylethyl)piperidine. Available at: http://www.ukchemicalresearch.org/Thread-Methoxphenidine-1-1-2-methoxyphenyl-2-phenylethyl-piperidine [7 January 2014].
199. H. Fujimura, K. Kawai . Pharmacological studies on diphenylalkylamine derivatives.(I). Bull. Inst. Chem. Res. Kyoto Univ. 1961, 39, 67.
200. R.L. Balster, G.E. Bigelow . Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 2003, 70, S13.
201. K. Schoedel, E. Sellers . Assessing abuse liability during drug development: Changing standards and expectations. Clin. Pharmacol. Ther. 2008, 83, 622.
202. R.H. Schwartz . Adolescent abuse of dextromethorphan. Clin. Pediatr. 2005, 44, 565.
203. C.J. Cording, R. DeLuca, T. Camporese, E. Spratt . A fatality related to the veterinary anesthetic telazol. J. Anal.Toxicol. 1999, 23, 552.
204. M.T. Quail, P. Weimersheimer, A.D. Woolf, B. Magnani . Abuse of telazol: An animal tranquilizer. Clin. Toxicol. 2001, 39, 399.
205. M. Klein, S. Calderon, B. Hayes . Abuse liability assessment of neuroprotectants. Ann. N.Y. Acad. Sci. 1999, 890, 515.
206. M.A. Javors, C.K. Erikson, W.M. Morgan . Addiction Potential of Abused Drugs and Drug Classes. Haworth Press, New York, 1990.
207. M. Muzet, P. D'Arbigny, R. Luthringer, M. Jhanwar-Uniyal, P.H. Boeijinga, J.M. Andrieux, J.P. Macher . Effects of gacyclidine, a non-competitive NMDA receptor antagonist, in human healthy volunteers. Soc. Neurosci. Abstr. 1999, 25, 1090.
208. M. Coppola, R. Mondola . Methoxetamine: From drug of abuse to rapid-acting antidepressant. Med. Hypotheses. 2012, 79, 504.
209. M. Coppola, R. Mondola . Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics? Med. Hypotheses. 2013, 81, 10.
210. A. Kalir . Structure activity relationships of phencyclidine derivatives, in PCP (phencyclidine): historical and current perspectives. (Eds: E. Domino ). NPP Books: Michigan, 1981, pp. 31-46.